Rogan: Trump ‘called me a liberal’ at White House

Joe Rogan said Trump called him a liberal at a White House event where the president signed an executive order on psychedelic drugs and discussed FDA approval for ibogaine. Rogan also criticized the U.S.-Iran conflict, saying Trump supporters feel betrayed by the administration’s shift from its "no more wars" stance. The article is largely political commentary, with limited direct market impact beyond the psychedelic-drug regulatory angle.

Analysis

The market read-through is less about one podcaster’s comments and more about the fragility of the coalition that kept Trump’s “anti-war” brand intact. When a prominent retail-political amplifier starts publicly expressing betrayal, it raises the odds that opposition to a broader Middle East escalation becomes more organized among younger, low-propensity voters who are disproportionately shaped by creator ecosystems. That matters because foreign-policy disappointment tends to bleed into approval more slowly than bread-and-butter issues, but once it hits, it can depress enthusiasm and turnout for months rather than days.

The psychedelic-drug angle is a quieter but more investable signal. Executive-order attention around ibogaine and related therapies can accelerate a regulatory path that is typically bottlenecked by FDA caution, but the first-order beneficiaries are not obvious “psychedelic stocks” so much as contract research, specialty clinical operators, and data/real-world evidence platforms that can monetize a longer approval cycle. The second-order effect is political: attaching the administration to a niche neuropsychiatry agenda gives it a bipartisan, health-reform veneer and could create a small but durable regulatory overhang for incumbents with exposure to mental-health treatment optionality.

The geopolitical piece still dominates near-term tape risk. A prolonged Strait of Hormuz disruption is an oil-volatility event first, but it also transmits into rates, inflation breakevens, and risk appetite within days; the more dangerous setup is not higher spot crude but rising policy uncertainty that delays Fed easing and compresses equity multiples. If talks fail, the market likely overreacts to headline escalation in the first 1-2 sessions, then reprices based on whether the blockade is symbolic or materially constraining flows over the next 2-6 weeks.

Contrarian view: the consensus may be underestimating how quickly a ceasefire narrative can reassert itself if negotiations resume, which would unwind any knee-jerk defense/energy bid. At the same time, the market may be overpricing the direct investability of psychedelic-policy headlines; without clearer FDA guidance, the order is more sentiment than cash-flow. The better trade is volatility around the geopolitics, not a blind thematic chase on the healthcare side.

Key Decisions for Investors

• Buy short-dated XLE or USO calls into any headline-driven pullback in the Iran talks, targeting a 2-4 week window; use a tight stop if diplomacy reopens and crude gaps lower, since the move is driven by event risk rather than fundamentals.
• Pair long XLE / short IWM for the next 1-2 months if the Strait of Hormuz stays constrained; higher energy prices and sticky inflation should pressure small-cap duration-sensitive multiples more than integrated energy cash flows.
• For tactical geopolitics hedging, buy SPY put spreads 1-2 months out financed partially by selling out-of-the-money calls; this is highest convexity if ceasefire talks fail and risk assets reprice lower on higher inflation expectations.
• If you want to express the psychedelic-regulation theme, prefer a basket of CROs / specialty trial enablers over single-name biotech longs; the risk/reward is better because the policy catalyst improves probability-weighted demand without requiring immediate commercialization.
• Fade any sharp 1-day selloff in defense names on ceasefire headlines only if confirmation remains absent; otherwise stay neutral, because the earnings upside from sustained regional tension is real but already partially reflected in expectations.